Mandate

Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech

October 29, 2018

Galecto Biotech AB, the developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, has closed a €79 million financing co-led by Ysios Capital and OrbiMed.

New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round.
 
Vinge advised the new investors. The Vinge team included Jesper Ottergren, Erik Sjöman and Charlotte Akej.
 

Anti-counterfeiting – the best way to work to counteract trademark infringement and counterfeiting

Counterfeiting and intellectual property law infringement constitute significant problems for both individual trademarks and companies as well as from a broader societal perspective. In this year’s edition of WTR’s “Anti-Counterfeiting: A Global Guide” we present the most important parts of the Swedish legislation, as well as how companies can create successful preventive measures.
June 07, 2021

Full service within IP gives top ranking

Vinge's IP team has been ranked in the top band by the international guide IP Stars in two areas; Trade mark contentious and Trade mark prosecution - law firms.
May 21, 2021

Extensive amendments to the Swedish Protective Security Act - increased obligations and a comprehensive sanctions system

Extensive amendments to the Swedish Protective Security, which include increased obligations for operators of security-sensitive activities and a comprehensive sanctions system, are proposed to enter into force on 1 December 2021. These changes, which were presented in a Government bill of 18 March 2021, generate new and far-reaching obligations for many companies, especially in view of the severe sanctions that may be imposed if the obligations are not complied with.
May 19, 2021